Biostream Gets FDA Breakthrough Designation for Urine Test for iNPH

News related to:Biostream · 2 min read

HAIFA, Israel, Nov. 18, 2026 /CourierPR/ -- Biostream, a company developing urine-based biomarker diagnostics for neurological care, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its urine test to aid in the diagnosis of idiopathic normal pressure hydrocephalus (iNPH). This designation, granted on November 12, 2026, is intended to give patients more timely access to a medical device that may provide more effective diagnosis or treatment of a life-threatening or irreversibly debilitating condition.

The test, which measures a panel of proteins in a urine sample and applies a proprietary algorithm, is intended for use by healthcare professionals, together with clinical assessment, to aid in the diagnosis of iNPH and its differentiation from Alzheimer's disease and other neurodegenerative disorders in patients aged 60 and older with signs and symptoms suggestive of NPH. The test is designed to add objective, biology-based information from a urine sample to help clinicians identify patients who may have iNPH and should be considered for further evaluation.

iNPH is a build-up of cerebrospinal fluid in the brain that causes walking difficulties, memory and thinking problems, and loss of bladder control. Unlike most causes of dementia-like symptoms, it can often be treated: shunt surgery to drain the excess fluid can bring substantial improvement, especially when performed early. Yet iNPH is frequently mistaken for Alzheimer's disease, Parkinson's disease, or normal aging. Studies estimate that iNPH affects about 2-4% of people aged 65 and older, and the Hydrocephalus Association reports that more than 80% of patients are unrecognized or untreated.

The test is designed to add objective, biology-based information from a urine sample to help clinicians identify patients who may have iNPH and should be considered for further evaluation. Biostream plans to conduct a prospective clinical validation study at U.S. academic medical centers during 2027.

The company, founded in 2025, combines urinary proteomics with machine learning to give clinicians objective, non-invasive tools for diagnosing and managing neurological disorders. Its first product addresses normal pressure hydrocephalus.

The Breakthrough Device Designation is not FDA clearance or approval and does not guarantee marketing authorization. The designation is intended to give patients more timely access to medical devices that may provide more effective diagnosis or treatment of life-threatening or irreversibly debilitating conditions, such as iNPH, and is part of the FDA's Breakthrough Devices Program, which provides priority review and more interactive engagement with FDA during development.

Biostream's test is an investigational device and is not currently available for sale in the United States.

Biostream's iNPH test is designed to add objective, non-invasive information from a urine sample to help clinicians identify patients who may have iNPH and should be considered for further evaluation. The test is intended for use by healthcare professionals, together with clinical assessment, to aid in the diagnosis of iNPH and its differentiation from Alzheimer's disease and other neurodegenerative disorders in patients aged 60 and older with signs and symptoms suggestive of NPH. The test is designed to add objective, biology-based information from a urine sample to help clinicians identify patients who may have iNPH and should be considered for further evaluation. The test is designed to add objective, biology-based information from a urine sample to help clinicians identify patients who may have iNPH and should be considered for further evaluation.

Start filing today

One press release free every week. No card required.

Create a free account